Characteristics of patients with BP-CML
| . | Myeloid, n = 276 . | Lymphoid, n = 129 . | Mixed phenotype, n = 13 . |
|---|---|---|---|
| Sex | |||
| Male | 163 | 91 | 7 |
| Female | 113 | 38 | 6 |
| Age at BP, y | |||
| Median | 49 | 48 | 50 |
| Range | 20-88 | 18-81 | 23-70 |
| Latency, mo* | |||
| Median | 19.2 | 8.9 | 1.0 |
| Range | 0-205 | 0-141 | 0-73 |
| OS after BP, mo | |||
| Median | 10.2 | 18.3 | 17.8 |
| Range | 0.03-183 | 0.03-181 | 0.2-126 |
| Status at last F/U | |||
| Alive | 61 | 45 | 3 |
| Dead | 215 | 84 | 10 |
| ACAs | |||
| No | 64 | 52 | 3 |
| Single | 100 | 39 | 7 |
| Complex | 112 | 38 | 3 |
| ACA emergence | |||
| Before BP | 79 | 15 | 1 |
| At BP | 86 | 41 | 8 |
| After BP | 47 | 21 | 1 |
| . | Myeloid, n = 276 . | Lymphoid, n = 129 . | Mixed phenotype, n = 13 . |
|---|---|---|---|
| Sex | |||
| Male | 163 | 91 | 7 |
| Female | 113 | 38 | 6 |
| Age at BP, y | |||
| Median | 49 | 48 | 50 |
| Range | 20-88 | 18-81 | 23-70 |
| Latency, mo* | |||
| Median | 19.2 | 8.9 | 1.0 |
| Range | 0-205 | 0-141 | 0-73 |
| OS after BP, mo | |||
| Median | 10.2 | 18.3 | 17.8 |
| Range | 0.03-183 | 0.03-181 | 0.2-126 |
| Status at last F/U | |||
| Alive | 61 | 45 | 3 |
| Dead | 215 | 84 | 10 |
| ACAs | |||
| No | 64 | 52 | 3 |
| Single | 100 | 39 | 7 |
| Complex | 112 | 38 | 3 |
| ACA emergence | |||
| Before BP | 79 | 15 | 1 |
| At BP | 86 | 41 | 8 |
| After BP | 47 | 21 | 1 |
Abbreviations are explained in Table 1.
Latency: time interval from initial diagnosis of CML to blastic transformation.